GlassScriptPhysician profile
Candace L Nesmith
NPI 1992275549
$4,118.71
in general payments reported to CMS, 2019-2025
45 companies · $2,505 in 2025
The $2,505 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $100 · 2023: $199 · 2024: $1,315 · 2025: $2,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548 · Education: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.83 |
| Education | $470.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $395.38 | 2024-2025 | Enhertu, Lynparza, Tagrisso |
| Novartis Pharmaceuticals Corporation | $300.70 | 2023-2025 | |
| Incyte Corporation | $300.37 | 2024-2025 | Jakafi, Niktimvo, Zynyz |
| Glaxosmithkline, LLC. | $265.19 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $223.57 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $215.80 | 2024-2025 | |
| Janssen Biotech, INC. | $211.25 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Daiichi Sankyo INC. | $201.60 | 2023-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $160.90 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Exelixis INC. | $138.90 | 2025 | Cabometyx |
| Genzyme Corporation | $137.09 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $135.45 | 2024-2025 | Ultomiris |
| Abbvie INC. | $127.86 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $102.68 | 2023-2025 | Libtayo, Lynozyfic |
| Sobi, INC | $91.62 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $77.99 | 2025 | |
| Agios Pharmaceuticals, INC. | $75.37 | 2024-2025 | Pyrukynd |
| Springworks Therapeutics, INC. | $69.96 | 2024-2025 | Ogsiveo, Gomekli |
| Astellas Pharma US INC | $65.54 | 2025 | Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $64.03 | 2023-2025 | Iclusig, Ninlaro |
| Deciphera Pharmaceuticals INC. | $54.92 | 2024-2025 | Qinlock, Tgct |
| Celgene Corporation | $50.38 | 2024-2025 | Reblozyl |
| Immunocore Limited | $48.63 | 2025 | Kimmtrak |
| Pharmacosmos Therapeutics INC. | $48.15 | 2024-2025 | Monoferric, Cosela |
| Beigene USA, INC. | $47.26 | 2024-2025 | Brukinsa, Tevimbra |
| Sumitomo Pharma America, INC. | $44.83 | 2024-2025 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $44.53 | 2024 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $41.58 | 2025 | Brukinsa, Tevimbra |
| Dendreon Pharmaceuticals LLC | $29.50 | 2025 | Provenge |
| Caris Mpi, INC. | $29.28 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $28.74 | 2025 | |
| Kite Pharma, INC. | $26.38 | 2025 | Yescarta |
| Karyopharm Therapeutics INC. | $25.67 | 2025 | Xpovio |
| Lilly USA, LLC | $24.83 | 2024 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $24.13 | 2024 | |
| Adaptive Biotechnologies Corporation | $23.24 | 2024 | Clonoseq |
| Geron Corporation | $22.74 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $22.40 | 2025 | |
| Seagen INC. | $20.80 | 2023 | Adcetris |
| Fennec Pharmaceuticals, INC. | $17.81 | 2025 | Fyarro |
| Pharmaessentia USA Corporation | $17.80 | 2024 | Besremi |
| Array Biopharma INC | $17.03 | 2025 | Braftovi, Mektovi |
| Bayer Healthcare Pharmaceuticals INC. | $16.34 | 2025 | |
| G1 Therapeutics, INC. | $15.46 | 2023 | Cosela |
| Coherus Oncology, INC. | $15.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Nesmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.